The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Recent Advances: the Cytochrome P450 Enzymes
Abstract
Successful application of information on cytochrome P450 to prevent drug interactions and improve the therapeutic risk: benefit ratio can occur only if we know which enzyme is responsible for the metabolism of a drug. Until recently, this information was not usually available when new drugs reached the market. It is not enough to know the fraction of a dose metabolized versus excreted unchanged or the metabolic pathways by which a compound is degraded. Studies conducted during drug development must identify the enzyme or enzymes involved in the metabolism of new drugs. In addition, the ability of new drugs to inhibit or induce the activity of the key P450 enzymes must be known if we are to take full advantage of our current knowledge of how the cytochrome P450 system works.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., et al. (1993) · DNA and Cell Biology · doi:10.1089/dna.1993.12.1 · Cited by 1,655
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
Wrighton, S. A., & Stevens, J. C. (1992) · Critical Reviews in Toxicology · doi:10.3109/10408449209145319 · Cited by 944
The P450 Gene Superfamily: Recommended Nomenclature
NEBERT, D. W., ADESNIK, M., COON, M. J., ESTABROOK, R. W., GONZALEZ, F. J., GUENGERICH, F. P., GUNSALUS, I. C., JOHNSON, E. F., KEMPER, B., LEVIN, W., et al. (1987) · DNA · doi:10.1089/dna.1987.6.1 · Cited by 818
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00025a009 · Cited by 601
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., & Guzelian, P. S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113156 · Cited by 480
Extrahepatic Metabolism of Drugs in Humans
Krishna, D. R., & Klotz, U. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426020-00007 · Cited by 437
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
Smith, C. A. D., Wolf, C. R., Gough, A. C., Spurr, N. K., Leigh, P. N., Summers, B. A., Harding, A. E., Maranganore, D. M., Sturman, S. G., Williams, A. C., et al. (1992) · The Lancet · doi:10.1016/0140-6736(92)91196-f · Cited by 417
Noninvasive tests of CYP3A enzymes
Watkins, P. B. (1994) · Pharmacogenetics · doi:10.1097/00008571-199408000-00001 · Cited by 408
Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., & Vandenbranden, M. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09441-6 · Cited by 402
Bertilsson, L., Lou, Y.-Q., Du, Y.-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L., & Sjöqvist, F. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.38 · Cited by 399
CYP3A gene expression in human gut epithelium
Kolars, J. C., Lown, K. S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S. A., Merion, R. M., & Watkins, P. B. (1994) · Pharmacogenetics · doi:10.1097/00008571-199410000-00003 · Cited by 365
Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Hartwell, P. S., Raisys, V. A., Marsh, C. L., McVicar, J. P., & Barr, D. M. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22834-8 · Cited by 355
Hebert, M. F., Roberts, J. P., Prueksaritanont, T., & Benet, L. Z. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.171 · Cited by 337
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities
Relling, M. V., Lin, J.-S., Ayers, G. D., & Evans, W. E. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.203 · Cited by 314
Wrighton, S. A., Stevens, J. C., Becker, G. W., & Vandenbranden, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1506 · Cited by 281
Wedlund, P. J., Aslanian, W. S., McAllister, C. B., Wilkinson, G. R., & Branch, R. A. (1984) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1984.256 · Cited by 263
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
Kalow, W., & Tang, B.-K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.176 · Cited by 261
Identification of Human Liver Cytochrome P450 Isoforms Mediating Omeprazole Metabolism
ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A., & BIRKETT, D. J. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb00410.x · Cited by 230
Characterization of human cytochrome P450 enzymes
Guengerich, F. P. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.2.1537465 · Cited by 227
Selective Inhibitors of Cytochromes P450
Halpert, J. R., Guengerich, F. P., Bend, J. R., & Correia, M. A. (1994) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1994.1061 · Cited by 214
Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking
Kalow, W., & Tang, B.-K. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.8 · Cited by 213
Campbell, M. E., Grant, D. M., Inaba, T., & Kalow, W. (1987) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06689-9 · Cited by 208
Dahl, M.-L., Johansson, I., Palmertz, M. P., Ingelman-Sundberg, M., & Sjöqvist, F. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.2 · Cited by 186
P450 Enzymes: Inhibition Mechanisms, Genetic Regulation and Effects of Liver Disease
Murray, M. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223020-00005 · Cited by 182
Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva
Fuhr, U., & Rost, K. L. (1994) · Pharmacogenetics · doi:10.1097/00008571-199406000-00001 · Cited by 181
Inaba, T., Jurima, M., Mahon, W. A., & Kalow, W. (1985) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08231-5 · Cited by 179
Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity
Peter Guengerich, F. (1994) · Toxicology Letters · doi:10.1016/0378-4274(94)90156-2 · Cited by 158
Chiba, K., Kobayashi, K., Manabe, K., Tani, M., Kamataki, T., & Ishizaki, T. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38328-x · Cited by 144
Fuhr, U., Anders, E. M., Mahr, G., Sörgel, F., & Staib, A. H. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.942 · Cited by 136
Watkins, P. B., Turgeon, D. K., Saenger, P. H., Lown, K. S., Kolars, J. C., Hamilton, T. A., Fishman, K., Guzelian, P. S., & Voorhees, J. J. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.140 · Cited by 135
Rost, K. L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H., & Roots, I. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.126 · Cited by 132
Characterization of dextromethorphan N-demethylation by human liver microsomes
Gorski, J. C., Jones, D. R., Wrighton, S. A., & Hall, S. D. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90237-2 · Cited by 130
Sohn, D., Kusaka, M., Ishizaki, T., et al. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.125 · Cited by 119
Rost, K. L., & Roots, I. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.49 · Cited by 112
Evans, W. E., Relling, M. V., Rahman, A., McLeod, H. L., Scott, E. P., & Lin, J. S. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116441 · Cited by 109
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.269.12.1513 · Cited by 102
Relling, M. V., Cherrie, J. W., Schell, M. J., Petros, W. P., Meyer, W. H., & Evans, W. E. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.141 · Cited by 100
Saxena, R., Shaw, G. L., Relling, M. V., Frame, J. N., Moir, D. T., Evans, W. E., Caporaso, N. E., & Weiffenbach, B. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.6.923 · Cited by 100
May, D. G., Porter, J., Wilkinson, G. R., & Branch, R. A. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.62 · Cited by 95
Fuhr, U., Strobl, G., Manaut, F., et al. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13599-2 · Cited by 94
Kadlubar, F. F. (1994) · Drug Metabolism Reviews · doi:10.3109/03602539409029783 · Cited by 79
Genetic Differences in Drug Disposition
May, D. G. (1994) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1994.tb04001.x · Cited by 57
Touchette, M., Chandrasekar, P., Milad, M., & Edwards, D. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04111.x · Cited by 57
Self-citationFirst, M. R., Schroeder, T. J., Michael, A., Hariharan, S., Weiskittel, P. D., & Alexander, J. (1993) · PubMed · Cited by 11
Cited by
(2007) · PubMed · Cited by 953
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
Ishizaki, & Horai (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00022.x · Cited by 428
Clinical Pharmacology of Midazolam in Infants and Children
Blumer, J. L. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835010-00003 · Cited by 313
Metadata
- Authors
- Slaughter, R. L., & Edwards, D. J.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1995-06
- Volume
- 29
- Issue
- 6
- Pages
- 619-624
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W201794629
- Cited by
- 274
- References
- 49
- FWCI
- 18.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.